HSCS HeartSciences Inc.
USHealthcareAs of 2026-07-10 16:00
Why HSCS matters now
HeartSciences Inc. (HSCS) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.74 with +2.24% on the session and $5.9M in market capitalization; recent performance reads 1-month -2.13% and YTD -40.45%.
The latest financial table shown here is Q3 2026, with revenue of $0.00, net income of $-2.0M, and EPS of $-0.63. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -85521.2%.
The latest indexable market news headline is "Fortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $3.00; recent insider activity includes Bent Bruce filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.19
P/S
460.00
EV/EBITDA
442.97
DCF Value
$-1.71
FCF Yield
-85521.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1060.2%
Operating Margin
-89939.6%
Net Margin
-97881.0%
ROE
-333.4%
ROA
-112.3%
ROIC
-119.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-2.0M | $-0.63 |
| Q2 2026 | $2.4K | $-2.4M | $-0.85 |
| Q1 2026 | $1.9K | $-2.1M | $-1.58 |
| Q4 2025 | $4.3K | $-2.1M | $-1.88 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$3.00
Target (Median)
$3.00
Target Range
$3.00 - $3.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.97
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.